Sana Biotechnology (NASDAQ:SANA) Shares Up 8.7% – Here’s What Happened
by Michael Walen · The Markets DailySana Biotechnology, Inc. (NASDAQ:SANA – Get Free Report)’s share price shot up 8.7% during trading on Monday . The stock traded as high as $3.71 and last traded at $3.8250. 1,232,656 shares changed hands during mid-day trading, a decline of 55% from the average session volume of 2,757,338 shares. The stock had previously closed at $3.52.
Analyst Ratings Changes
SANA has been the topic of several research reports. Wedbush increased their target price on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sana Biotechnology in a research note on Tuesday, April 14th. Wall Street Zen lowered Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Bank of America increased their target price on Sana Biotechnology from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Finally, Zacks Research lowered Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 3rd. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.20.
View Our Latest Stock Analysis on Sana Biotechnology
Sana Biotechnology Stock Performance
The company has a market cap of $984.75 million, a price-to-earnings ratio of -3.80 and a beta of 2.06. The business has a 50-day simple moving average of $3.46 and a 200-day simple moving average of $4.13.
Sana Biotechnology (NASDAQ:SANA – Get Free Report) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). Research analysts anticipate that Sana Biotechnology, Inc. will post -0.59 EPS for the current year.
Institutional Investors Weigh In On Sana Biotechnology
A number of hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. increased its holdings in shares of Sana Biotechnology by 180.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after acquiring an additional 1,375,029 shares during the last quarter. Baillie Gifford & Co. increased its holdings in shares of Sana Biotechnology by 13.6% in the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock valued at $40,600,000 after acquiring an additional 1,371,775 shares during the last quarter. Integral Health Asset Management LLC increased its holdings in shares of Sana Biotechnology by 33.3% in the 3rd quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock valued at $7,100,000 after acquiring an additional 500,000 shares during the last quarter. Rafferty Asset Management LLC purchased a new position in shares of Sana Biotechnology in the 3rd quarter valued at about $951,000. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Sana Biotechnology in the 3rd quarter valued at about $100,000. Institutional investors and hedge funds own 88.23% of the company’s stock.
Sana Biotechnology Company Profile
Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.
The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.